Facilitating Access to Approved Medication
Get Access To Lutetium Lu 177 Vipivotide Tetraxetan Solution For Infusion
Lutetium Lu 177 Vipivotide Tetraxetan Solution For Infusion
- API: lutetium Lu 177 vipivotide tetraxetan
- Trade Name: On Request
- Packaging: injection
- Strength: For Injection: Injection: 1,000 MBq/mL (27 mCi/mL) in a single-dose vial.
What is Lutetium Lu 177 Vipivotide Tetraxetan Solution For Infusion used for?
Lutetium is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Lutetium (177Lu) vipivotide tetraxetan was approved for medical use in the United States in March 2022, and in the European Union in December 2022.
Note: (For Prescribing Information Approved Drugs, see)
- The Food and Drug Administration (FDA), USA.
- The European Medicines Agency (EMA).
All Trademarks and Brands that appear on website belong to their respective owners does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Lutetium Lu 177 Vipivotide Tetraxetan Solution For Infusion is a pharmaceutical drug To access this medicine, a prescription of your treating doctor is necessary.. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.